Viewing Study NCT02201459

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:49 PM
Ignite Modification Date: 2026-03-12 @ 10:43 AM
Study NCT ID: NCT02201459
Status: COMPLETED
Last Update Posted: 2025-10-02
First Post: 2014-06-24
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients
Sponsor: Hospices Civils de Lyon
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Myeloid Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Peg-IFN, nilotinib, MR4.5, CML, chronic phase, first-line View